Abstract 585P
Background
Mobocertinib is a tyrosine kinase inhibitor (TKI) for patients with locally advanced and metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) exon 20 insertion (exon20ins) mutations previously treated with platinum-based chemotherapy. This study aimed to generate real-world (RW) data on the effectiveness of mobocertinib.
Methods
A retrospective chart review of patients in the compassionate use program was conducted in 3 countries (Canada, France, Hong Kong; 29 sites). Inclusion criteria: ≥18 years old; diagnosis of stage IIIB-IV NSCLC with EGFR exon20ins mutations between 1 Jan 2017 and 30 Nov 2021; received mobocertinib. Data on demographics, lung cancer characteristics, mobocertinib treatment, disease outcomes and adverse events were abstracted from medical records. RW outcomes (progression free survival [PFS], overall response rate [ORR], duration of response, time to treatment discontinuation, overall survival) were calculated.
Results
In total, 105 patients were enrolled (mean [standard deviation, SD] age at initial diagnosis: 62.4 years [11.27]; N [%]: women: 66 [62.9%]; Canada: 19 [18.1%]; France: 51 [48.6%]; Hong Kong: 35 [33.3%]; Stage IV at advanced diagnosis: 97 [94.2%]; brain metastasis during study: 57 [54.3%]). Most patients received mobocertinib as 2nd or 3rd line of therapy (78 [74.3%]); maximum daily dose (N patients (%)): 160mg: 71 (67.6%), 120mg: 16 (15.2%), 80mg: 8 (7.6%), 40mg: 6 (5.7%), unknown: 4 (3.8%). The median PFS (95% confidence interval [CI]) was 4.76 months (3.98, 6.21; N: 105). The ORR was 20.0%, and the median DOR was 8.34 months (95% CI: 3.61, 9.49; N: 21). There was cross-country variation in RW outcomes (Table). In total, 51 patients (48.6%) reported diarrhea (all grades) related to mobocertinib (treatment discontinuation due to diarrhea: 4 patients [7.8%]). Table: 585P
RW outcomes for all patients and by country (data reported as median [95% CI] months except overall response rate (ORR), presented as number (%) of patients with complete / partial response)
RW Outcome | All patients (N: 105) | Canada (N: 19) | France (N: 51) | Hong Kong (N: 35) |
Progression Free Survival | 4.76 [3.98, 6.21] | 6.05 [3.12, 8.74] | 3.75 [2.07, 5.03] | 6.41 [4.11, 11.50] |
ORR | 21 (20.0%) | 7 (36.8%) | 9 (17.6%) | 5 (14.3%) |
Duration of response | 8.34 [3.61, 9.49] | 7.95 [2.00, NA] | 9.23 [1.18, NA] | 7.72 [2.10, NA] |
Time to treatment discontinuation | 4.50 [3.45, 6.08] | 5.19 [2.50, 12.16] | 3.45 [1.91, 4.93] | 6.83 [4.14, 11.37] |
Overall survival | 26.28 [20.21, 36.44] | 36.30 [20.14, 50.04] | 19.65 [14.59, 30.75] | 37.65 [24.38, 49.97] |
Conclusions
Patients had favorable RW outcomes suggesting clinical effectiveness of mobocertinib.
Clinical trial identification
NCT05207423; 12 Jan 2022.
Editorial acknowledgement
Zaneta Stawiarska (IQVIA).
Legal entity responsible for the study
Takeda Development Center Americas, Inc., Lexington, MA, USA.
Funding
Takeda Development Center Americas, Inc.
Disclosure
T.S.K. Mok: Financial Interests, Personal, Advisory Role: AbbVie, ACEA Pharma, Alpha Biopharma, Amgen, AstraZeneca, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Blueprint Medicines, CStone Pharmaceuticals, Daiichi Sankyo, Eisai, Fishawack Facilitate, GeneDecode, Gritstone Oncology Inc., Guardant Health, Hengrui Therapeutics, Ignyta Inc., IQVIA, Incyte, Janssen, Lilly, Loxo Oncology, Lunit USA, Merck Serono, Merck Sharp & Dohme, Mirati Therapeutics, MORE Health, Novartis, OrigiMed, Pfizer, Puma Biotechnology, Roche, Sanofi-Aventis R&D, Takeda, Virtus Medical Group, Yuhan Corp., SFJ Pharmaceuticals, Curio Science, Inivata, Berry Oncology, G1 Therapeutics Inc., Qiming Development (HK) Ltd., Gilead Sciences, Vertex Pharmaceuticals, Covidien LP, Elevation Oncology, C4 Therapeutics, Amoy Diagnostics Co.; Financial Interests, Personal, Invited Speaker: ACEA Pharma, Alpha Biopharma Co, Amgen, Amoy Diagnostics, AstraZeneca, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Fishawack Facilitate, GeneDecode, InMed Medical Communication, Janssen, Lilly, Lunit USA, MD Health, Medscape/WebMD, Merck Serono, MSD, Novartis, OrigiMed, PeerVoice, Physicians’ Education Resource, P Permanyer SL, Pfizer, PrIME Oncology, Research to Practice, Roche, Sanofi-Aventis R&D, Takeda, Touch Medical Media, Daz Group, Lucence Health, Merck Pharmaceuticals HK Ltd., Shanghai BeBirds Translation & Consulting Co, Llangylhul Network Technology Co., Taiho; Financial Interests, Personal, Member of Board of Directors: Lunit USA, AstraZeneca PLC, Hutchison Chi-Med, Act Genomics-Sanomics Group, Aurora; Financial Interests, Personal, Stocks/Shares: Hutchison Chi-Med, Act Genomics-Sanomics Group, Aurora; Financial Interests, Personal, Funding, Grant: Clovis Oncology, Xcovery. G. Liu: Non-Financial Interests, Personal, Other, Honraria: Takeda, Amgen, AstraZeneca, Roche, Novartis, Merck, Pfizer, Jazz Pharmaceuticals; Financial Interests, Institutional, Funding, research grants: Takeda, AstraZeneca, Amgen, Boehringer Ingelheim. H. Curcio: Financial Interests, Personal, Other, Honoraria or consultations fees: Bristol Myers Squibb; Financial Interests, Personal, Other, Registration fees and accommodation: Sandoz. A. Cortot: Financial Interests, Personal, Advisory Board: AbbVie, Amgen, AstraZeneca, BMS, Exeliom Biosciences, InhaTarget Therapeutics, Sanofi, Roche, Pfizer, Novartis, Merck, Janssen, Takeda. R. Descourt: Financial Interests, Personal, Advisory Board: AZ, BMS, MSD, Pfizer, Sanofi, Takeda. P.K. Cheema: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Bayer, Novartis, Roche, Pfizer, Janssen, Merck; Financial Interests, Personal, Other, Honorarium: GSK, Janssen, Sanofi, Merck. J.M. Gwinnutt: Financial Interests, Personal and Institutional, Full or part-time Employment: IQVIA. E.N. Churchill, J. Nyborn, E. Curran, Y. Yin, K. Chong, Y. Tanaka-Chambers, J. Kretz: Financial Interests, Personal and Institutional, Full or part-time Employment: Takeda. J. Cadranel: Financial Interests, Personal, Advisory Board: Amgen, AZ, BI, BMS, Janssen, MSD, Novartis, Pfizer, Sanofi, Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
461P - A randomized controlled trial of yoga in locally advanced non-small cell lung cancer patients receiving chemoradiotherapy
Presenter: Indranil Khan
Session: Poster Display
Resources:
Abstract
462P - Cognitive function of survivors with non-central nervous system cancer and its correlates: A community rehabilitation perspective
Presenter: Ann Kuo
Session: Poster Display
Resources:
Abstract
463P - The use of antipsychotic for managing delirium in patients with cancer
Presenter: Natasya Reina
Session: Poster Display
Resources:
Abstract
464P - The prevalence and correlates of frailty and pre-frailty in elderly patients with breast cancer: A cross-sectional study from China
Presenter: Min Xiao
Session: Poster Display
Resources:
Abstract
465P - Oncological care needs of people with mental illness: A single institution experience in Australia
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
466P - Identification of patient satisfaction predictors among women attending oncology daycare unit using validated survey questionnaire (PSS Tool): An institutional experience in central India
Presenter: Rajesh Patidar
Session: Poster Display
Resources:
Abstract
467P - Evaluation of the effectiveness of a cluster management model based on evidence-based concepts in oncology nutrition case management
Presenter: Li He
Session: Poster Display
Resources:
Abstract
468P - The patterns of use of Traditional Chinese Medicine (TCM) in cancer patients in Hong Kong
Presenter: Olivia L T Chan
Session: Poster Display
Resources:
Abstract
469P - The need of special care for adolescent and young adult (AYA) cancer survivors: Perspective from oncologists in India
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
470TiP - Randomised controlled trial to evaluate the efficacy and safety of moisturising creams with or without palm-oil-derived vitamin E concentrate in addition to urea-based cream or urea-based cream alone in Capecitabine-associated Palmar-Plantar Erythrodysesthesia (ECaPPE)
Presenter: Pei-Jye Voon
Session: Poster Display
Resources:
Abstract